182 related articles for article (PubMed ID: 38171988)
21. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Hodgson DR; Dougherty BA; Lai Z; Fielding A; Grinsted L; Spencer S; O'Connor MJ; Ho TW; Robertson JD; Lanchbury JS; Timms KM; Gutin A; Orr M; Jones H; Gilks B; Womack C; Gourley C; Ledermann J; Barrett JC
Br J Cancer; 2018 Nov; 119(11):1401-1409. PubMed ID: 30353044
[TBL] [Abstract][Full Text] [Related]
22. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
Zhu H; Wei M; Xu J; Hua J; Liang C; Meng Q; Zhang Y; Liu J; Zhang B; Yu X; Shi S
Mol Cancer; 2020 Mar; 19(1):49. PubMed ID: 32122376
[TBL] [Abstract][Full Text] [Related]
23. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
[TBL] [Abstract][Full Text] [Related]
24. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
[TBL] [Abstract][Full Text] [Related]
25. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
26. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
Lin ZP; Ratner ES; Whicker ME; Lee Y; Sartorelli AC
Mol Cancer Res; 2014 Mar; 12(3):381-393. PubMed ID: 24413181
[TBL] [Abstract][Full Text] [Related]
27. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Watkins JA; Irshad S; Grigoriadis A; Tutt AN
Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
[TBL] [Abstract][Full Text] [Related]
28. Abrogation of KLF5 sensitizes
Zhang Z; Liu Y; Xu Y; Xu Z; Jia J; Jin Y; Wang W; Liu L
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):576-585. PubMed ID: 38433576
[TBL] [Abstract][Full Text] [Related]
29. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
30. Integrating PARP inhibitors into the management of breast cancer: where are we?
Azim HA; Kassem L; Azim H
Chin Clin Oncol; 2021 Jan; 10(5):50. PubMed ID: 33440946
[TBL] [Abstract][Full Text] [Related]
31. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
[TBL] [Abstract][Full Text] [Related]
32. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
[TBL] [Abstract][Full Text] [Related]
33. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
34. The role of PARP inhibitors in
Chi J; Chung SY; Parakrama R; Fayyaz F; Jose J; Saif MW
Therap Adv Gastroenterol; 2021; 14():17562848211014818. PubMed ID: 34025781
[TBL] [Abstract][Full Text] [Related]
35. An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Cortesi L; Rugo HS; Jackisch C
Target Oncol; 2021 May; 16(3):255-282. PubMed ID: 33710534
[TBL] [Abstract][Full Text] [Related]
36. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
Kasi A; Al-Jumayli M; Park R; Baranda J; Sun W
J Pancreat Cancer; 2020; 6(1):107-115. PubMed ID: 33376937
[No Abstract] [Full Text] [Related]
37. [Homologous recombination deficiency and PARP inhibitors in therapeutics].
Salaün H; Saint-Ghislain M; Bellesoeur A; Beuzeboc P; Neuzillet C; Diéras V; Stern MH; Rodrigues M
Bull Cancer; 2022 Jan; 109(1):76-82. PubMed ID: 34799081
[TBL] [Abstract][Full Text] [Related]
38. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Gourley C; Miller RE; Hollis RL; Ledermann JA
Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
[TBL] [Abstract][Full Text] [Related]
39. PARP inhibition in treatment of pancreatic cancer.
Hammel P; Zhang C; Matile J; Colle E; Hadj-Naceur I; Gagaille MP; Bouattour M; Cros J; de Mestier L; Lamuraglia M
Expert Rev Anticancer Ther; 2020 Nov; 20(11):939-945. PubMed ID: 32936674
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
Rodler E; Sharma P; Barlow WE; Gralow JR; Puhalla SL; Anders CK; Goldstein L; Tripathy D; Brown-Glaberman UA; Huynh TT; Szyarto CS; Godwin AK; Pathak HB; Swisher EM; Radke MR; Timms KM; Lew DL; Miao J; Pusztai L; Hayes DF; Hortobagyi GN
Lancet Oncol; 2023 Feb; 24(2):162-174. PubMed ID: 36623515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
